Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Withdrawn 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3Thoracic 2Head & Neck 2Other solid neoplasm 1Gynecologic 1Genitourinary 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Colorectal Neoplasms 476Carcinoma, Non-Small-Cell Lung 233Breast Neoplasms 196Ovarian Neoplasms 171Glioblastoma 157Carcinoma, Hepatocellular 131Neoplasms 128Rectal Neoplasms 114Colonic Neoplasms 110Neoplasm Metastasis 106Brain Neoplasms 98Lung Neoplasms 96Fallopian Tube Neoplasms 85Carcinoma, Renal Cell 77Glioma 69Pancreatic Neoplasms 54Liver Neoplasms 44Melanoma 43Gliosarcoma 43Uterine Cervical Neoplasms 40Adenocarcinoma of Lung 39Stomach Neoplasms 37Recurrence 33Astrocytoma 30Carcinoma, Ovarian Epithelial 28Endometrial Neoplasms 27Triple Negative Breast Neoplasms 26Kidney Neoplasms 23Prostatic Neoplasms 22Esophageal Neoplasms 21

Interventions

pembrolizumab 29avelumab 21Nivolumab 20Ipilimumab 10Radiotherapy 9Cyclophosphamide 9atezolizumab 8cemiplimab 7fludarabine 6Specimen Handling 6durvalumab 5aldesleukin 5Radiation 5Magnetic Resonance Spectroscopy 5Interleukin-2 5Biopsy 5talimogene laherparepvec 4ALT-803 4poly ICLC 3Radiosurgery 3Etoposide 3Cisplatin 3Carboplatin 3CTLA-4 Antigen 3Bevacizumab 3prednylidene 2lutetium Lu 177 dotatate 2fludarabine phosphate 2domatinostat 2deltacortene 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Carcinoma, Merkel Cell × Bevacizumab × Clear all
NCT03074513 2026-03-11

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
133 enrolled
DermatologicEndocrineHead & NeckOther solid neoplasmThoracic

Nasopharyngeal Carcinoma, Mesothelioma, Malignant, Adenocarcinoma, Mucinous, Adenoma, Islet Cell, Nasopharyngeal Neoplasms, Carcinoma, Merkel Cell, Carcinoma, Neuroendocrine

NCT06047379 2026-03-02

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Neonc Technologies, Inc.

Phase 1/2 Recruiting
134 enrolled
CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Astrocytoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Central Nervous System Neoplasms, Small Cell Lung Carcinoma

NCT03167164 2025-02-21

QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy

ImmunityBio, Inc.

Phase 1/2 Withdrawn
Dermatologic

Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡